Xin Hua Cai Jing·2025-04-24 10:38Core Insights - China National Pharmaceutical Group has 12 clinical studies selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) annual meeting, with 4 studies included in the "Latest Breakthrough Abstracts" [2][3] - The ASCO annual meeting is recognized as a leading global event in clinical oncology, showcasing over 40 innovative results from China National Pharmaceutical Group, covering more than 10 innovative drugs in various advanced fields such as ADC and bispecific antibodies [2] - Among the 12 oral presentations, 4 studies focus on "Bemarituzumab + Anlotinib Capsules," while 5 studies involve Anlotinib alone or in combination with other therapies [2] Group 1 - The phase III clinical study comparing "Bemarituzumab + Anlotinib" to Pembrolizumab for first-line treatment of PD-L1 positive advanced non-small cell lung cancer has been selected for the "Latest Breakthrough Abstract," with data to be presented on June 1 [2] - Two additional phase III studies on "Bemarituzumab + Anlotinib" for consolidation therapy after synchronous or sequential chemoradiotherapy and for first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer have also been selected for oral presentation [2] Group 2 - The HER2 bispecific antibody ADC drug TQB2102 will present its first human study data for advanced solid tumors at the ASCO meeting [3] - The ASCO meeting is scheduled to take place from May 30 to June 3 in Chicago, USA, with over 50 studies from 22 Chinese pharmaceutical companies selected for oral presentations [3] - Most abstract content will be published on the conference website on May 22, apart from the "Latest Breakthrough Abstracts" [3]